Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and drug development company Aparna Biosciences Corp. (AparnaBio) (Rockville, MD) today announced a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.
Omnia Biologics (Omnia) is a contract manufacturer focused on process development and clinical trials material manufacturing of innovative biopharmaceuticals. AparnaBio is developing a new class of proprietary nanomedicine drug delivery technology.
“Despite recent setbacks in lentivirus based drug development on the business side, we continue to see great promise in the platform.” Dr. Dale VanderPutten, CEO, Omnia Biologics, Inc. commented on the deal. “The AparnaBio team has deep experience, a level of sophistication and a track record of success that gives them a leg up on successfully executing on the commercial potential of the lentivirus drug delivery concept. We are pleased to be chosen by AparnaBio as a partner in this development effort.”
From farm to pharmacy: Transgenic cow milk as a new source of human insulin